How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Staked-in Needle Prefilled Syringe Market
- By Needle Gauge Size: 21G, 23G, 25G, 27G, 30G
- By Syringe Volume Capacity: 0.5 mL, 1 mL, 2.5 mL, 3 mL, 5 mL
- By Needle Length: 8 mm, 12 mm, 16 mm, 25 mm, 38 mm
- By Material Type: Glass Barrel, Plastic Barrel
- By Application: Insulin Delivery, Vaccination, Biologics Administration, Hormone Therapy, Anesthetics
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - 21G leads By Needle Gauge Size at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 300 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.181 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.189 →
Full report · locked preview
Everything inside the Staked-in Needle Prefilled Syringe Market report
A complete, evidence-based study - 12 chapters and 126 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Needle Gauge Size 5
Syringe Volume Capacity 5
Needle Length 5
Material Type 2
Application 5
Companies profiled
BD (Becton
Dickinson and Company)
Terumo Corporation
Owen Mumford Ltd.
Gerresheimer AG
Nipro Corporation
SCHOTT AG
Ypsomed AG
West Pharmaceutical Services Inc.
Noble International Inc.
Unilife Corporation
Vetter Pharma International GmbH
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →BD (Becton
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Dickinson and Company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Terumo Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Owen Mumford Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Gerresheimer AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Nipro Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →SCHOTT AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Ypsomed AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →West Pharmaceutical Services Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Noble International Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Unilife Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Vetter Pharma International GmbH
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Sino Biopharmaceutical Limited
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Sartorius AG
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Catalent Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Nemera
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$10,790M by 2033 · 11.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- 21G45.2
- 23G12.9
- 25G20.2
- 27G9.9
- 30G11.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,504M → $3,258M · 10.1%
Europe$1,049M → $2,324M · 10.5%
Asia Pacific$957.4M → $2,036M · 9.9%
Latin America$592.7M → $1,551M · 12.8%
Middle East and Africa$455.9M → $1,048M · 11.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →11.332026
11.342027
11.352028
11.362029
11.362030
11.392031
11.392032
11.402033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- BD (Becton15.0
- Dickinson and Company)22.5
- Terumo Corporation4.5
- Owen Mumford Ltd.5.9
- Gerresheimer AG14.1
- Nipro Corporation9.9
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Needle Gauge Size16.6%
Syringe Volume Capacity24.3%
Needle Length24.2%
Material Type20.0%
Application14.9%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.9
- Europe22.7
- Asia Pacific19.9
- Latin America15.2
- Middle East and Africa10.3
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| BD (Becton | 81 | 93 | 76 | 99 | 85 | 98 | 89 |
| Dickinson and Company) | 76 | 84 | 90 | 70 | 80 | 87 | 81 |
| Terumo Corporation | 63 | 74 | 86 | 64 | 71 | 63 | 70 |
| Owen Mumford Ltd. | 68 | 77 | 73 | 77 | 64 | 82 | 74 |
| Gerresheimer AG | 60 | 54 | 59 | 74 | 52 | 52 | 59 |
| Nipro Corporation | 53 | 64 | 49 | 46 | 54 | 66 | 55 |
| SCHOTT AG | 47 | 51 | 56 | 51 | 57 | 56 | 53 |
| Ypsomed AG | 59 | 40 | 53 | 39 | 40 | 45 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- BD (Becton
- Dickinson and Company)
- Terumo Corporation
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| BD (Becton | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Dickinson and Company) | ◐ | ✓ | ✓ | ◐ | ✓ | ✓ |
| Terumo Corporation | ◐ | ◐ | ✓ | ◐ | ◐ | − |
| Owen Mumford Ltd. | ◐ | ◐ | ◐ | ◐ | ◐ | ✓ |
| Gerresheimer AG | − | − | − | ✓ | ◐ | ◐ |
| Nipro Corporation | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| SCHOTT AG | − | − | ◐ | − | − | ◐ |
| Ypsomed AG | ◐ | − | ◐ | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1BD (Becton89
2Dickinson and Company)81
3Owen Mumford Ltd.74
4Terumo Corporation70
5Gerresheimer AG59
6Nipro Corporation55
7SCHOTT AG53
8Ypsomed AG46
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
BD (BectonDickinson and Company)
Challenger2
Strong scale, closing on the leaders.
Terumo CorporationOwen Mumford Ltd.
Contender1
Focused players with pockets of strength.
Gerresheimer AG
Niche3
Specialists in a single segment or region.
Nipro CorporationSCHOTT AGYpsomed AG
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Needle Gauge Size in North America, then scale across Staked-in Needle Prefilled Syringe Market — a $217M beachhead inside a $2.90B market.
Beachhead (SOM)$217Mobtainable near-term
Serviceable (SAM)$1.16Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
21G
Best fit — highest urgency & budget in Needle Gauge Size.
Economic buyer78 fit
23G
Strong fit — clear ROI and a fast path to value.
End user68 fit
25G
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Needle Gauge Size in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Syringe Volume Capacity & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Needle Length
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel27%
Digital / self-serve19%
Marketplaces10%
Positioning & messaging
§GTM 2 · p.194 →For Needle Gauge Size leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Staked-in Needle Prefilled Syringe Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified45%
Sales qualified25%
Evaluation13%
Closed-won6%
$17.0KCAC
$81KLTV
4.8:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Staked-in Needle Prefilled Syringe Market is a durable-growth opportunity — $1.14B by 2033, compounding at 7.9%.
TAM · 2025$616Mtoday
TAM · 2033$1.14Bforecast
CAGR7.9%2027–2033
Cumulative$7.67Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.14BTotal addressable market
SAM$448MServiceable available market
SOM$78MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.9% CAGR
Demand compounds through 2033, outpacing GDP across Needle Gauge Size.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Needle Gauge Size moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.14BLarge & growingTAM by 2033 at 7.9% CAGR
$448MServiceable nowreachable with today’s model
$78MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$886MBear5.2% CAGR
$1.14BBase7.9% CAGR
$1.45BBull10.5% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Syringe Volume Capacity optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Staked-in Needle Prefilled Syringe Market — a $9.90B market by 2033. Plan: grow share from 6.0% to 13.1%.
Market size · 2033$9.90Btotal addressable
Market CAGR9.3%2027–2033
Target share13.1%from 6.0% today
Revenue ambition$1.30Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.0% | 13.1% | At risk |
| Revenue | $543M | $1.30B | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Ahead |
| Gross margin | 37.4% | 39.3% | Ahead |
| Customer retention | 84.4% | 93.6% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Needle Gauge Size
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Syringe Volume Capacity capability
A defensible second engine — invest in Syringe Volume Capacity to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Needle Gauge Size share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Syringe Volume Capacity
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $144M capacity & capability investment
- Greenlight bolt-on M&A in Syringe Volume Capacity
- Authorise North America expansion plan
- Fund R&D program for Needle Gauge Size leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeBehind
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Staked-in Needle Prefilled Syringe Market conversation — a $6.24B market you can size, segment and defend in minutes.
Market size · 2033$6.24Btotal opportunity
Growth8.4%CAGR to 2033
Addressable buyers1,454+accounts in scope
Typical ROI6.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Needle Gauge Size
Goal Grow share in Needle Gauge Size
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.5×return on cost, year one
< 2 mopayback period
$49K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
BD (BectonDickinson and Company)Terumo CorporationOwen Mumford Ltd.Gerresheimer AGNipro CorporationSCHOTT AGYpsomed AG+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Staked-in Needle Prefilled Syringe Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Staked-in Needle Prefilled Syringe Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Stair-treadmill Ergometer Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportStairlifts Rental Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportStair Lifts and Climbing Devices Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportStair Exercise Machines Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportStair-climbing Transfer Chair Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportStair Climber Machines Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportStair Chair Stretcher Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportStainless Steel Surgical Tubing Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportStainless Steel Surgical Scalpel Market
Market size, share, segmentation and regional forecast.
$565M market · 2025 base year
View reportStainless Steel Surgical Blades Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportStainless Steel Scalpel Handle Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportStainless Steel Safety Scalpel Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.